These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
117 related articles for article (PubMed ID: 118069)
41. The timing of tuberculin tests in relation to immunization with live viral vaccines. Brickman HF; Beaudry PH; Marks MI Pediatrics; 1975 Mar; 55(3):392-6. PubMed ID: 1143978 [TBL] [Abstract][Full Text] [Related]
42. Measles and rubella in Virginia: age shifts bring new problems. Hayden GF Va Med; 1983 Jun; 110(6):374-7. PubMed ID: 6880368 [No Abstract] [Full Text] [Related]
43. [The practicability of vaccinations]. Janetschek R Fortschr Med; 1977 Jan; 95(2):84-6. PubMed ID: 401761 [TBL] [Abstract][Full Text] [Related]
45. [Morbidity, vaccine coverage and immunity against measles, mumps and rubella in a Gallician population from 2 to 5 years old]. Vázquez Fernández E; López Rois F; Vázquez Carrete JA; Gómez Tato B; Alvarez Ares M An Esp Pediatr; 1987 Jul; 27(1):27-31. PubMed ID: 3662251 [TBL] [Abstract][Full Text] [Related]
46. Costs and benefits of measles vaccination in Finland. Ekblom M; Elo O; Laurinkari J; Niemelä P Scand J Soc Med; 1978; 6(3):111-5. PubMed ID: 103198 [TBL] [Abstract][Full Text] [Related]
47. [Mass vaccination against rubella in Iceland after cost-benefit analysis]. Olafsson O Nord Med; 1979 Sep; 94(8-9):203. PubMed ID: 113774 [No Abstract] [Full Text] [Related]
48. Systematic Review of Health Economic Analyses of Measles and Rubella Immunization Interventions. Thompson KM; Odahowski CL Risk Anal; 2016 Jul; 36(7):1297-314. PubMed ID: 25545778 [TBL] [Abstract][Full Text] [Related]
50. The cost saving opportunity of introducing a card review into measles-containing vaccination campaigns. Hagedorn BL; Dabbagh A; McCarthy KA Vaccine; 2019 Sep; 37(41):6093-6101. PubMed ID: 31471145 [TBL] [Abstract][Full Text] [Related]
51. Enabling implementation of the Global Vaccine Action Plan: developing investment cases to achieve targets for measles and rubella prevention. Thompson KM; Strebel PM; Dabbagh A; Cherian T; Cochi SL Vaccine; 2013 Apr; 31 Suppl 2():B149-56. PubMed ID: 23598476 [TBL] [Abstract][Full Text] [Related]
52. [Analysis on costs-benefits of vaccination against measles (author's transl)]. Porro de' Somenzi C Ann Sclavo; 1979 Jun; 21 Suppl 1():373-6. PubMed ID: 117757 [TBL] [Abstract][Full Text] [Related]
54. [Antimeasles and antirubella vaccinations]. Reginster-Haneuse G; Schaus N Rev Med Liege; 1968 Jul; 23(14):436-8. PubMed ID: 5740812 [No Abstract] [Full Text] [Related]
55. Vaccination against measles and other viral diseases. Dunlop JM Public Health; 1985 May; 99(3):137-40. PubMed ID: 4034908 [No Abstract] [Full Text] [Related]
57. Has the measles campaign been a wise use of resources? Powell C Br J Nurs; 1995 Jan 12-25; 4(1):25-6. PubMed ID: 7881248 [No Abstract] [Full Text] [Related]
59. To screen or to vaccinate? A decision analysis for rubella prevention on campus. Chan CW J Am Coll Health; 1986 Nov; 35(3):116-21. PubMed ID: 3102583 [No Abstract] [Full Text] [Related]
60. Cost-benefit analysis of alternative programs of vaccination against rubella in Israel. Golden M; Shapiro GL Public Health; 1984 May; 98(3):179-90. PubMed ID: 6429710 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]